Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases

被引:27
作者
Gencheva, Radosveta [1 ]
Cheng, Qing [1 ]
Arner, Elias S. J. [1 ,2 ]
机构
[1] Karolinska Inst, Dept Med Biochem & Biophys, Div Biochem, S-17177 Stockholm, Sweden
[2] Natl Inst Oncol, Dept Selenoprot Res, Natl Tumor Biol Lab, H-1122 Budapest, Hungary
基金
瑞典研究理事会;
关键词
REDOX-ACTIVE DRUG; MAMMALIAN THIOREDOXIN; MOTEXAFIN GADOLINIUM; GLUTATHIONE-REDUCTASE; RHEUMATOID-ARTHRITIS; ESCHERICHIA-COLI; DOUBLE-BLIND; SCHISTOSOMA-MANSONI; PHASE-II; RECOMBINANT SELENOPROTEINS;
D O I
10.1016/j.freeradbiomed.2022.07.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human thioredoxin reductase (TrxR) is a selenoprotein with a central role in cellular redox homeostasis, utilizing a highly reactive and solvent-exposed seleno-cysteine (Sec) residue in its active site. Pharmacological modulation of TrxR can be obtained with several classes of small compounds showing different mechanisms of action, but most often dependent upon interactions with its Sec residue. The clinical implications of TrxR modulation as mediated by small compounds have been studied in diverse diseases, from rheumatoid arthritis and ischemia to cancer and parasitic infections. The possible involvement of TrxR in these diseases was in some cases serendipitously discovered, by finding that existing clinically used drugs are also TrxR inhibitors. Inhibiting isoforms of human TrxR is, however, not the only strategy for human disease treatment, as some pathogenic parasites also depend upon Sec-containing TrxR variants, including S. mansoni, B. malayi or O. volvulus. Inhibiting parasite TrxR has been shown to selectively kill parasites and can thus become a promising treatment strategy, especially in the context of quickly emerging resistance towards other drugs. Here we have summarized the basis for the targeting of selenoprotein TrxR variants with small molecules for therapeutic purposes in different human disease contexts. We discuss how Sec engagement appears to be an indispensable part of treatment efficacy and how some therapeutically promising compounds have been evaluated in preclinical or clinical studies. Several research questions remain before a wider application of selenoprotein TrxR inhibition as a first-line treatment strategy might be developed. These include further mechanistic studies of downstream effects that may mediate treatment efficacy, identification of isoform-specific enzyme inhibition patterns for some given therapeutic compounds, and the further elucidation of cell-specific effects in disease contexts such as in the tumor microenvironment or in host-parasite interactions, and which of these effects may be dependent upon the specific targeting of Sec in distinct TrxR isoforms.
引用
收藏
页码:320 / 338
页数:19
相关论文
共 43 条
  • [1] THIOREDOXIN AND THIOREDOXIN REDUCTASE IN THE PATHOGENESIS OF SELECTED HUMAN DISEASES, PART II
    Popielarski, Marcin
    Ponamarczuk, Halszka
    Kusinska, Katarzyna
    Swiatkowska, Maria
    POSTEPY BIOLOGII KOMORKI, 2015, 42 (01) : 159 - 179
  • [2] Thioredoxin glutathione reductase: Its role in redox biology and potential as a target for drugs against neglected diseases
    Prast-Nielsen, Stefanie
    Huang, Hsin-Hung
    Williams, David L.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2011, 1810 (12): : 1262 - 1271
  • [3] A New Member of the Thioredoxin Reductase Family from Early Oxygenic Photosynthetic Organisms
    Buey, Ruben M.
    Galindo-Trigo, Sergio
    Lopez-Maury, Luis
    Velazquez-Campoy, Adrian
    Luis Revuelta, Jose
    Javier Florencio, F.
    de Pereda, Jose M.
    Schurmann, Peter
    Buchanan, Bob B.
    Balsera, Monica
    MOLECULAR PLANT, 2017, 10 (01) : 212 - 215
  • [4] Potential drug targets and treatment of schizophrenia
    Kumar, Anil
    Yadav, Monu
    Parle, Milind
    Dhingra, Sameer
    Dhull, Dinesh K.
    INFLAMMOPHARMACOLOGY, 2017, 25 (03) : 277 - 292
  • [5] Thioredoxin Glutathione Reductase as a Novel Drug Target: Evidence from Schistosoma japonicum
    Song, LiJun
    Li, JiaHuang
    Xie, ShuYing
    Qian, ChunYan
    Wang, Jie
    Zhang, Wei
    Yin, XuRen
    Hua, ZiChun
    Yu, ChuanXin
    PLOS ONE, 2012, 7 (02):
  • [6] Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads
    Kaminska, Kamila K.
    Bertrand, Helene C.
    Tajima, Hisashi
    Stafford, William C.
    Cheng, Qing
    Chen, Wan
    Wells, Geoffrey
    Arner, Elias S. J.
    Chew, Eng-Hui
    ONCOTARGET, 2016, 7 (26) : 40233 - 40251
  • [7] Lichen Acids May Be Used as A Potential Drug For Cancer Therapy; by Inhibiting Mitochondrial Thioredoxin Reductase Purified From Rat Lung
    Ozgencli, Ilknur
    Budak, Harun
    Ciftci, Mehmet
    Anar, Mustafa
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (11) : 1599 - 1605
  • [8] Colchicine for the treatment of cardiovascular diseases: old drug, new targets
    Andreis, Alessandro
    Imazio, Massimo
    De Ferrari, Gaetano Maria
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2021, 22 (01) : 1 - 8
  • [9] Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity -: Effects on thioredoxin reductase and glutathione reductase
    Björkhem-Bergman, L
    Jönsson, K
    Eriksson, LC
    Olsson, JM
    Lehmann, S
    Paul, C
    Björnstedt, M
    BIOCHEMICAL PHARMACOLOGY, 2002, 63 (10) : 1875 - 1884
  • [10] EM23, a natural sesquiterpene lactone, targets thioredoxin reductase to activate JNK and cell death pathways in human cervical cancer cells
    Shao, Fang-Yuan
    Wang, Sheng
    Li, Hong-Yu
    Chen, Wen-Bo
    Wang, Guo-Cai
    Ma, Dong-Lei
    Wong, Nai Sum
    Xiao, Hao
    Liu, Qiu-Ying
    Zhou, Guang-Xiong
    Li, Yao-Lan
    Li, Man-Mei
    Wang, Yi-Fei
    Liu, Zhong
    ONCOTARGET, 2016, 7 (06) : 6790 - 6808